In a head-to-head study of two supra-annular, self-expanding TAVR devices, CoreValve Evolut (Medtronic) appears to be a better option than the Acurate neo valve (Boston Scientific) for the treatment ...

DUBLIN and SAN DIEGO - Medtronic plc today announced initial clinical outcomes for its next-generation CoreValve® Evolut(TM) R System. At 30-days, the new recapturable, self-expanding valve showed no ...

Surgical aortic valve replacement (SAVR) devices are widely believed to be considerably more durable than transcatheter aortic valve replacement (TAVR) devices, but five-year data for Medtronic plc’s ...

In patients with symptomatic severe aortic stenosis at intermediate or higher surgical risk, CoreValve or Evolut transcatheter aortic valve implantation (TAVI) was associated with a lower 5-year ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...

The Medtronic CoreValve Evolut R transcatheter aortic valve replacement system has received FDA approval. Medtronic and Edwards Lifesciences continue the transcatheter aortic valve replacement (TAVR) ...

The University of Michigan Frankel Cardiovascular Center is one of the first hospitals in the country to implant Medtronic's new investigational device during transcatheter aortic valve replacement ...

CHICAGO -- Tweaks made to Medtronic's CoreValve transcatheter heart valve (THV) line in the last few years have tracked with some improved outcomes after transcatheter aortic valve replacement (TAVR), ...

The 1-year follow-up analysis of the doubly randomized SOLVE-TAVI trial uncovered no reason, necessarily, to prefer either of two recent-generation valve prostheses for transcatheter aortic-valve ...